Advertisement
Canada markets open in 6 hours 47 minutes
  • S&P/TSX

    21,172.38
    -45.15 (-0.21%)
     
  • S&P 500

    4,981.80
    +6.29 (+0.13%)
     
  • DOW

    38,612.24
    +48.44 (+0.13%)
     
  • CAD/USD

    0.7433
    +0.0026 (+0.35%)
     
  • CRUDE OIL

    78.25
    +0.34 (+0.44%)
     
  • Bitcoin CAD

    69,730.49
    +224.59 (+0.32%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,040.70
    +6.40 (+0.31%)
     
  • RUSSELL 2000

    1,994.74
    -9.40 (-0.47%)
     
  • 10-Yr Bond

    4.3250
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,817.25
    +280.50 (+1.60%)
     
  • VOLATILITY

    15.34
    -0.08 (-0.52%)
     
  • FTSE

    7,662.51
    -56.70 (-0.73%)
     
  • NIKKEI 225

    39,098.68
    +836.52 (+2.19%)
     
  • CAD/EUR

    0.6848
    +0.0006 (+0.09%)
     

Global Hemp Group Announces Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at MD Anderson Cancer Center, as Its Chief Scientific Advisor

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce the appointment of Dr. Herbert Fritsche to the Company's Advisory Board as its Chief Scientific Advisor. Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas MD Anderson Cancer Center for 41 years.

Dr. Fritsche served as an invited consultant/advisor to the Food and Drug Administration, the National Cancer Institute, the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, the Editorial Board of six international scientific journals, and as a consultant to many major international diagnostic companies. Previously, he served on the Expert Panel for developing Tumor Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO) from its inception until his retirement from MD Anderson Cancer Center.

His awards include the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry, the Abbott-ISOBM Award for Outstanding Research in Oncology, the Morton K. Schwartz Award for Outstanding Achievements in the field of Cancer Diagnostics from the American Association for Clinical Chemistry ("AACC"), the Carl Jolliff Award for Lifetime Achievements in Immunology and Immunodiagnostics from the Immunology Division of the AACC, the Morton K. Schwartz Award for significant contributions to the development of cancer diagnostics from the New York Metro Division of the AACC, the Outstanding Clinical Chemist Award by the Texas Section of the AACC, the National Award for Contributions in Education by the AACC, the Dean's Excellence Award from the University of Texas Graduate School of Biomedical Science, and the Distinguished Scientist Award from the Clinical Ligand Assay Society ("CLAS").

Dr. Fritsche has served as President of the CLAS and various national committees for both the CLAS and AACC. He is a Fellow of the National Academy of Clinical Biochemistry.

He has published over 200 peer-reviewed scientific papers, invited articles and book chapters, and participated in the validation and FDA clearance process for many commercial serum cancer markers currently in use in the United States. Dr. Fritsche holds three patents and two patents pending.

Dr. Fritsche has lectured extensively for many years at international and national meetings of medical and professional societies, and he is recognized internationally as an expert in the field of clinical chemistry, cancer diagnostics and laboratory medicine.

Dr Fritsche stated, "I am pleased to continue working with Stephen Barnhill, Jr. and I look forward to now working with him to expand GHG's efforts to sublicense the exclusively licensed unique intellectual property from Apollon Formularies, plc on the natural biologic pharmaceutical formulations for cancer, inflammatory diseases and chronic pain, thereby, increasing accessibility of these products to help patients around the world where they are legal."

"Dr. Fritsche is a highly respected international authority in clinical chemistry and one of the world's leading experts on cancer biomarkers, whom I have had the honor of working with for more than 10 years. We are extremely pleased that he has agreed to join GHG's Advisory Board as our Chief Scientific Advisor ("CSA")," stated Stephen D. Barnhill, Jr. CEO of Global Hemp Group, "As GHG's CSA, Dr. Fritsche will be leading all scientific aspects of GHG's global licensing program for the intellectual property portfolio GHG recently licensed from Apollon."

About Global Hemp Group Inc.

Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) is focused on executing a multi-phased strategy to become a leader in the industrial hemp industry. To further support and innovate, GHG has established a R&D Division to actively pursue the development of Intellectual Property that can be patented for implementation at its projects and beyond. The Division is led by Prof. Víctor M. Castaño, Ph.D., whose career has focused in the areas of applied science and technology. The R&D team will initially focus on development of Environmentally Friendly Construction Materials, Nano Fertilizers and Enhanced Extraction from Hemp.

Cautionary Note Regarding Forward-Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Global Hemp Group Inc., including, but not limited to, the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, dependence upon regulatory approvals, the availability of future financing and exploration risk, and the legality of cannabis and hemp. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of Page 2 of 2 preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Except as required by law, Global Hemp Group Inc. disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For Further Information Contact Global Hemp Group

Investor Relations

Tel: 778-726-2900 info@globalhempgroup.com

www.globalhempgroup.com

Subscribe to the GHG YouTube Channel: https://www.youtube.com/channel/UCtjFn9dOyHMxJee-_37MTrw

Like us on Facebook: https://www.facebook.com/globalhempgrp

Follow us on Instagram: https://www.instagram.com/hemp_global/

Follow us on Twitter: https://twitter.com/Hemp_Global

Connect with us on LinkedIn: https://www.linkedin.com/company/18596421

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/159400